Gene-and Cell Therapies in Oncology
29-30 November 2021, Amsterdam (Netherlands)
Gene and cell therapy in oncology is a relatively new treatment approach that is in constant development. For this reason, the CDDF decided to organise this multi-stakeholder hybrid workshop that will outline how to generate the gene and cell “cancer killer” and will present some of the challenges involved in the clinical trials and in the marketing authorization of these therapies. Additionally, there will be a focus on how to improve patient access to the treatment and on the future perspectives of this innovative therapeutic approach.
The 2 half days meeting consists of 4 plenary sessions and adequate discussion and networking occasions. Each session will also include various perspectives of academics, regulatory agencies, patient advocates and industry and discuss the achievements and challenges involved in the gene and cell therapies in oncology.
- To understand the current landscape of Gene & Cell Therapy in oncology, with a focus on advances in drug development.
- To explore regulatory aspects, challenges and pathways now and in the future for the development and approval of innovative Gene & Cell Therapies.
- To understand the patient perspectives and challenges with Gene & Cell Therapies
- To explore the future perspectives related to Gene & Cell therapy in oncology
- Catarina Edfjäll (CDDF Board, CH)
- Darko Milijkovic (GSK, CH)
- Simona Paratore (Bovartis, IT)
- Martina Schuesller-Lenz (PEI, DE)
- Hans Scheurer (MPE, BE)
- Natacha Bolaños (Lymhoma Coalition, ES)
The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), pharmaceutical Industry, HTAs and patient advocates.
Click here to view the latest version of the scientific programme
Van der Valk Hotel Amsterdam – Amstel
Address: Joan Muyskenweg 20, 1096 CJ Amsterdam, Netherlands
Phone: +31 (0)20 800 1100